Table 3.
Main variables of the study in patients before and after treatment and correlations with serum FABP3 and FABP4 levels
| Characteristic | Before treatment, r (p value) | After treatment, r (p value) | ||
|---|---|---|---|---|
| FABP3 | FABP4 | FABP 3 | FABP4 | |
| SR (mm/h) | 0.156 (0.36) | 0.04 (0.82) | −0.197 (0.24) | 0.05 (0.75) |
| WBC (×103/ml) | 0.366 (0.03)* | 0.04 (0.82) | −0.191 (0.26) | 0.07 (0.65) |
| ALT (IU/l) | 0.230 (0.17) | 0.14 (0.42) | −0.168 (0.32) | 0.41 (0.01)* |
| AST (IU/l) | 0.333 (0.04)* | 0.15 (0.38) | 0.367 (0.025)* | 0.06 (0.73) |
| PLT (×103/ml) | 0.110 (0.50) | 0.21 (0.22) | −0.293 (0.08) | 0.15 (0.37) |
| BMI (kg/m2) | 0.260 (0.12) | 0.22 (0.19) | −0202 (0.23) | 0.33 (0.04)* |
| RBC (×103/ml) | 0.041 (0.80) | 0.01 (0.95) | 0.113 (0.50) | 0.10 (0.54) |
| Glucose level (mg/dl) | −0.0002 (0.99) | 0.07 (0.68) | −0.019 (0.91) | 0.14 (0.39) |
| CRP (mg/l) | 0.049 (0.77) | 0.03 (0.84) | 0.065 (0.70) | 0.21 (0.21) |
| Cholesterol (mg/dl) | 0.090 (0.73) | 0.09 (0.73) | 0.172 (0.51) | 0.03 (0.89) |
| HDL-C (mg/dl) | 0.107 (0.68) | 0.36 (0.16) | 0.062 (0.81) | 0.46 (0.06) |
| LDL-C (mg/dl) | 0.065 (0.80) | 0.38 (0.13) | 0.054 (0.84) | −0.09 (0.71) |
| TAG (mg/dl) | 0.054 (0.84) | 0.06 (0.82) | −0.015 (0.95) | −0.29 (0.25) |
| Adiponectin | −0.007 (0.96) | −0.02 (0.91) | −0.114 (0.50) | −0.04 (0.77) |
| Leptin | 0.004 (0.99) | 0.11 (0.51) | 0.227 (0.17) | 0.16 (0.32) |
| RBP-4 | 0.067 (0.69) | −0.38 (0.02)* | −0146 (0.38) | −0.35 (0.03)* |
| FABP3 | – | 0.15 (0.37) | – | 0.29 (0.08)* |
| FABP4 | 0.150 (0.37) | – | 0.29 (0.08)* | – |
| Age (years) | −0.001 (0.99) | −0.07 (0.67) | −0.040 (0.813) | 0.05 (0.75) |
| Relapse duration (months) | 0.170 (0.31) | 0.18 (0.29) | 0.244 (0.15) | −0.01 (0.92) |
| Disease duration (years) | −0.217 (0.20) | −0.15 (0.39) | 0.202 (0.23) | 0.02 (0.93) |
* Statistically significant correlation (p < 0.05), p values obtained by Spearman correlation